Susquehanna Fundamental Investments’s BioMarin Pharmaceuticals BMRN Stock Holding History

Susquehanna Fundamental Investments’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-63,104	Closed	-$4.46M	–	753
2025 Q1	$4.46M	Sell	63,104 -106,375	-63%	-$7.16M	0.06%	344
2024 Q4	$11.1M	Buy	+169,479	New	+$11.4M	0.16%	167
2024 Q2	$5.63M	Buy	+68,346	New	+$5.69M	0.13%	206
2023 Q2	–	Sell	-21,627	Closed	-$2.1M	–	667
2023 Q1	$2.1M	Sell	21,627 -18,969	-47%	-$1.97M	0.05%	362
2022 Q4	$4.2M	Sell	40,596 -92,748	-70%	-$8.71M	0.07%	332
2022 Q3	$11.3M	Buy	+133,344	New	+$11.9M	0.19%	147
2022 Q1	$2.77M	Buy	35,910 +3,630	+11%	+$304K	0.05%	465
2021 Q4	$2.85M	Sell	32,280 -48,550	-60%	-$4.01M	0.07%	328
2021 Q3	$6.25M	Buy	+80,830	New	+$6.38M	0.11%	237

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Susquehanna Fundamental Investments's BMRN Position: Q2 2025 in Review

Susquehanna Fundamental Investments sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2025, closing a stake of 63,104 shares — an estimated $4.46M sold.

Susquehanna Fundamental Investments first reported a position in BMRN in Q3 2021 and held it in 9 quarters. The position peaked at $11.3M in Q3 2022. 582 funds tracked by Wall St. Rank hold BMRN as of Q2 2025.

Susquehanna Fundamental Investments reported no remaining BioMarin Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Susquehanna Fundamental Investments sold 63,104 BioMarin Pharmaceuticals shares in Q2 2025, an estimated $4.46M.
Susquehanna Fundamental Investments first reported a position in BioMarin Pharmaceuticals in Q3 2021 and held it in 9 quarters.
Susquehanna Fundamental Investments's BioMarin Pharmaceuticals position peaked at $11.3M in Q3 2022.
582 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2025.

Based on Susquehanna Fundamental Investments's 13F filing for Q2 2025, filed 14 Aug 2025.